Health Care · Biotechnology
Jazz Pharmaceuticals Iberia S.L. revenue, results and funding
Jazz Pharmaceuticals Iberia S.L. filed revenue of $4.3B for 2025.
Data updated Nov 19, 2026 · Back to the company report
$4.3BRevenue, 2025
−$356.1MNet income, 2025
Results by year
| Year | Revenue | Net income | Total assets | LANG_CR_S_M_TAX_PAID | LANG_CR_S_M_TAX_EXPENSE | LANG_CR_S_M_BUYBACKS | LANG_CR_S_M_CAPEX | LANG_CR_S_M_SBC | LANG_CR_S_M_RND | LANG_CR_S_M_OPERATING_INCOME | LANG_CR_S_M_CASH | LANG_CR_S_M_DEBT | LANG_CR_S_M_ACQUISITIONS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $4.3B | −$356.1M | $11.7B | $121.8M | −$272.4M | $125M | $58.8M | $291.1M | $782.7M | −$430.2M | $1.4B | $4.3B | – |
| 2024 | $4.1B | $560.1M | $12B | $114.9M | −$91.4M | $311.4M | $38.1M | $248M | $884M | $716.6M | $2.4B | $6.1B | – |
| 2023 | $3.8B | $414.8M | $11.4B | $177.9M | −$119.9M | $269.8M | $24M | $226.8M | $849.7M | $578.6M | $1.5B | $5.1B | $0 |
| 2022 | $3.7B | −$224.1M | $10.8B | $94.7M | −$158.6M | $54k | $29M | $222M | $590.5M | −$65.5M | $881.5M | $5.7B | $0 |
| 2021 | $3.1B | −$329.7M | $12.3B | $271.2M | $216.1M | $0 | $27.6M | $189M | $505.7M | $170.3M | $591.4M | $6B | $6.2B |
| 2020 | $2.4B | $238.6M | $6.5B | $226.8M | $33.5M | $146.5M | $15M | $121M | $335.4M | $378.1M | $1.1B | $1.8B | $0 |
| 2019 | $2.2B | $523.4M | $5.5B | $183.6M | −$73.2M | $301.5M | $40.1M | $110.6M | $299.7M | $532.4M | $637.3M | $1.6B | $0 |
| 2018 | $1.9B | $447.1M | $5.2B | $164.2M | $80.2M | $523.7M | $20.4M | $102.4M | $226.6M | $614.8M | $309.6M | $1.6B | $0 |
| 2017 | $1.6B | $487.8M | $5.1B | $174.1M | −$47.7M | $98.8M | $29M | $106.9M | $198.4M | $528.8M | $386M | $1.5B | $0 |
| 2016 | $1.5B | $396.8M | $4.8B | $160.3M | $135.2M | $278.3M | $9.7M | $98.8M | $162.3M | $591.7M | $366M | $2B | $1.5B |
| 2015 | $1.3B | $329.5M | $3.3B | $145.6M | $106.4M | $61.6M | $36M | $91.6M | $135.3M | $508.2M | $988.8M | $1.2B | $0 |
| 2014 | $1.2B | $58.4M | $3.3B | $108.2M | $94.2M | $42.2M | $36.3M | $69.6M | $85.2M | $195.6M | $684M | $1.3B | $828.7M |
| 2013 | $872.4M | $216.3M | $2.2B | $137.6M | $91.6M | $136.5M | $10M | $44.6M | $41.6M | $340.3M | $636.5M | $544.4M | $0 |
| 2012 | $586M | $288.6M | $2B | $9.1M | −$83.8M | $0 | $6M | $23M | $20.5M | $197.8M | $387.2M | $427.1M | $542.5M |
| 2011 | $272.3M | $125M | $253.6M | $0 | $0 | $0 | $1.3M | $20.7M | $14.1M | $127.8M | $82.1M | $0 | $0 |
Sources: SEC
How to cite
Jazz Pharmaceuticals Iberia S.L., Financials. Alion, Nov 19, 2026. https://alion.io/company/jazzpharma/financials
